The group warned of a potential “explosion in the unlicensed sale of medication online” and stated that consumers were endangering their health by acquiring Ozempic and Wegovy (semaglutide) without sufficient screening.
Ozempic is accessible on the NHS for adults with type 2 diabetes, while Wegovy can be prescribed for weight loss through specialist weight management programs, subject to strict eligibility criteria.
However, the punches have grown in popularity, with social media users posting before and after photographs of fat loss, and some celebrities have encouraged their use.
Although Ozempic, a Novo Nordisk product, helps people with type 2 diabetes control their blood sugar levels, some have been using it to reduce their appetite and lose weight. The drug is in low supply, according to pharmacists, and some doctors are writing off-label prescriptions for obese patients. This is due to consumer demand. This has led to a shortage for those with diabetes, while also fueling an increase in counterfeit jabs.
